NASDAQ:UCBB

US-China Biomedical Technology Competitors

$0.34
+0.21 (+169.84 %)
(As of 04/19/2021 11:30 AM ET)
Add
Compare
Today's Range
$0.34
Now: $0.34
$0.34
50-Day Range
$0.10
MA: $0.18
$0.35
52-Week Range
$0.01
Now: $0.34
$0.35
Volume187 shs
Average Volume1,063 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

US-China Biomedical Technology (NASDAQ:UCBB) Vs. AAPL, MSFT, GOOG, GOOGL, FB, and TSM

Should you be buying UCBB stock or one of its competitors? Companies in the sector of "computer and technology" are considered alternatives and competitors to US-China Biomedical Technology, including Apple (AAPL), Microsoft (MSFT), Alphabet (GOOG), Alphabet (GOOGL), Facebook (FB), and Taiwan Semiconductor Manufacturing (TSM).

US-China Biomedical Technology (NASDAQ:UCBB) and Apple (NASDAQ:AAPL) are both computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares US-China Biomedical Technology and Apple's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
US-China Biomedical TechnologyN/AN/AN/AN/AN/A
Apple$274.52 billion8.24$57.41 billion$3.2841.06

Apple has higher revenue and earnings than US-China Biomedical Technology.

Analyst Ratings

This is a breakdown of recent ratings and price targets for US-China Biomedical Technology and Apple, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
US-China Biomedical Technology0000N/A
Apple282702.68

Apple has a consensus target price of $137.0058, indicating a potential upside of 1.31%. Given Apple's higher probable upside, analysts clearly believe Apple is more favorable than US-China Biomedical Technology.

Profitability

This table compares US-China Biomedical Technology and Apple's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
US-China Biomedical TechnologyN/AN/AN/A
Apple20.91%75.15%17.63%

Institutional & Insider Ownership

57.8% of Apple shares are held by institutional investors. 0.1% of Apple shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Apple beats US-China Biomedical Technology on 8 of the 8 factors compared between the two stocks.

US-China Biomedical Technology (NASDAQ:UCBB) and Microsoft (NASDAQ:MSFT) are both computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for US-China Biomedical Technology and Microsoft, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
US-China Biomedical Technology0000N/A
Microsoft022923.00

Microsoft has a consensus price target of $269.9867, suggesting a potential upside of 3.98%. Given Microsoft's higher possible upside, analysts clearly believe Microsoft is more favorable than US-China Biomedical Technology.

Earnings & Valuation

This table compares US-China Biomedical Technology and Microsoft's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
US-China Biomedical TechnologyN/AN/AN/AN/AN/A
Microsoft$143.02 billion13.68$44.28 billion$5.7645.03

Microsoft has higher revenue and earnings than US-China Biomedical Technology.

Profitability

This table compares US-China Biomedical Technology and Microsoft's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
US-China Biomedical TechnologyN/AN/AN/A
Microsoft32.28%40.74%16.23%

Insider & Institutional Ownership

69.0% of Microsoft shares are held by institutional investors. 0.1% of Microsoft shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Microsoft beats US-China Biomedical Technology on 9 of the 9 factors compared between the two stocks.

US-China Biomedical Technology (NASDAQ:UCBB) and Alphabet (NASDAQ:GOOG) are both computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Profitability

This table compares US-China Biomedical Technology and Alphabet's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
US-China Biomedical TechnologyN/AN/AN/A
Alphabet20.80%17.31%12.68%

Insider & Institutional Ownership

31.9% of Alphabet shares are owned by institutional investors. 13.0% of Alphabet shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for US-China Biomedical Technology and Alphabet, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
US-China Biomedical Technology0000N/A
Alphabet012102.95

Alphabet has a consensus price target of $2,334.0556, suggesting a potential upside of 1.35%. Given Alphabet's higher possible upside, analysts plainly believe Alphabet is more favorable than US-China Biomedical Technology.

Earnings and Valuation

This table compares US-China Biomedical Technology and Alphabet's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
US-China Biomedical TechnologyN/AN/AN/AN/AN/A
Alphabet$161.86 billion9.59$34.34 billion$51.5644.63

Alphabet has higher revenue and earnings than US-China Biomedical Technology.

Summary

Alphabet beats US-China Biomedical Technology on 8 of the 8 factors compared between the two stocks.

US-China Biomedical Technology (NASDAQ:UCBB) and Alphabet (NASDAQ:GOOGL) are both computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Institutional and Insider Ownership

33.8% of Alphabet shares are owned by institutional investors. 13.2% of Alphabet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares US-China Biomedical Technology and Alphabet's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
US-China Biomedical TechnologyN/AN/AN/A
Alphabet20.80%17.31%12.68%

Analyst Recommendations

This is a breakdown of current ratings for US-China Biomedical Technology and Alphabet, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
US-China Biomedical Technology0000N/A
Alphabet014002.98

Alphabet has a consensus target price of $2,159.9512, indicating a potential downside of 5.71%. Given Alphabet's higher probable upside, analysts plainly believe Alphabet is more favorable than US-China Biomedical Technology.

Valuation and Earnings

This table compares US-China Biomedical Technology and Alphabet's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
US-China Biomedical TechnologyN/AN/AN/AN/AN/A
Alphabet$161.86 billion9.53$34.34 billion$51.5644.37

Alphabet has higher revenue and earnings than US-China Biomedical Technology.

Summary

Alphabet beats US-China Biomedical Technology on 8 of the 8 factors compared between the two stocks.

Facebook (NASDAQ:FB) and US-China Biomedical Technology (NASDAQ:UCBB) are both computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

Analyst Recommendations

This is a summary of current ratings and price targets for Facebook and US-China Biomedical Technology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Facebook153612.86
US-China Biomedical Technology0000N/A

Facebook presently has a consensus target price of $327.2564, indicating a potential upside of 8.76%. Given Facebook's higher probable upside, equities research analysts plainly believe Facebook is more favorable than US-China Biomedical Technology.

Institutional and Insider Ownership

65.0% of Facebook shares are owned by institutional investors. 14.1% of Facebook shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Facebook and US-China Biomedical Technology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Facebook32.00%23.27%18.12%
US-China Biomedical TechnologyN/AN/AN/A

Earnings and Valuation

This table compares Facebook and US-China Biomedical Technology's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Facebook$70.70 billion12.09$18.49 billion$6.4346.67
US-China Biomedical TechnologyN/AN/AN/AN/AN/A

Facebook has higher revenue and earnings than US-China Biomedical Technology.

Summary

Facebook beats US-China Biomedical Technology on 9 of the 9 factors compared between the two stocks.

Taiwan Semiconductor Manufacturing (NYSE:TSM) and US-China Biomedical Technology (NASDAQ:UCBB) are both computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.

Institutional and Insider Ownership

18.3% of Taiwan Semiconductor Manufacturing shares are owned by institutional investors. 1.1% of Taiwan Semiconductor Manufacturing shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Taiwan Semiconductor Manufacturing and US-China Biomedical Technology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Taiwan Semiconductor Manufacturing37.94%28.73%20.16%
US-China Biomedical TechnologyN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and target prices for Taiwan Semiconductor Manufacturing and US-China Biomedical Technology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Taiwan Semiconductor Manufacturing21602.44
US-China Biomedical Technology0000N/A

Taiwan Semiconductor Manufacturing currently has a consensus price target of $106.75, indicating a potential downside of 8.17%. Given Taiwan Semiconductor Manufacturing's higher probable upside, analysts clearly believe Taiwan Semiconductor Manufacturing is more favorable than US-China Biomedical Technology.

Earnings & Valuation

This table compares Taiwan Semiconductor Manufacturing and US-China Biomedical Technology's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Taiwan Semiconductor Manufacturing$34.63 billion17.32$11.83 billion$3.3934.12
US-China Biomedical TechnologyN/AN/AN/AN/AN/A

Taiwan Semiconductor Manufacturing has higher revenue and earnings than US-China Biomedical Technology.

Summary

Taiwan Semiconductor Manufacturing beats US-China Biomedical Technology on 8 of the 8 factors compared between the two stocks.


US-China Biomedical Technology Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Apple logo
AAPL
Apple
2.2$134.67+0.1%$2.26 trillion$274.52 billion41.31Analyst Report
Insider Selling
Microsoft logo
MSFT
Microsoft
2.5$259.40+0.3%$1.95 trillion$143.02 billion41.91Upcoming Earnings
Analyst Report
Alphabet logo
GOOG
Alphabet
1.7$2,301.36+0.0%$1.55 trillion$161.86 billion44.47Upcoming Earnings
Analyst Report
Analyst Revision
Alphabet logo
GOOGL
Alphabet
1.8$2,287.67+0.1%$1.54 trillion$161.86 billion44.21Upcoming Earnings
Analyst Report
Analyst Revision
Facebook logo
FB
Facebook
1.8$300.06+0.7%$860.68 billion$70.70 billion34.18Analyst Report
Insider Selling
Analyst Revision
News Coverage
Taiwan Semiconductor Manufacturing logo
TSM
Taiwan Semiconductor Manufacturing
1.5$115.67+0.2%$598.47 billion$34.63 billion34.02Analyst Upgrade
Analyst Revision
NVIDIA logo
NVDA
NVIDIA
2.1$613.39+0.2%$382.44 billion$10.92 billion100.39Analyst Report
PayPal logo
PYPL
PayPal
1.9$269.43+0.6%$314.60 billion$17.77 billion101.67Analyst Report
ASML logo
ASML
ASML
1.7$626.25+0.6%$264.53 billion$13.24 billion70.05Upcoming Earnings
Analyst Downgrade
Increase in Short Interest
Intel logo
INTC
Intel
2.2$63.28+0.6%$259.12 billion$71.97 billion12.41Upcoming Earnings
Adobe logo
ADBE
Adobe
1.9$514.61+0.3%$246.73 billion$12.87 billion47.47
Verizon Communications logo
VZ
Verizon Communications
2.2$58.17+0.4%$241.73 billion$131.87 billion12.62Upcoming Earnings
Analyst Revision
Oracle logo
ORCL
Oracle
2.1$78.94+0.2%$227.08 billion$39.07 billion23.92Decrease in Short Interest
Cisco Systems logo
CSCO
Cisco Systems
2.4$52.02+1.6%$223.12 billion$49.30 billion21.15Analyst Report
AT&T logo
T
AT&T
2.3$29.93+0.2%$213.88 billion$181.19 billion19.69Upcoming Earnings
Analyst Revision
salesforce.com logo
CRM
salesforce.com
1.9$229.74+0.3%$212.29 billion$17.10 billion59.98Insider Selling
Broadcom logo
AVGO
Broadcom
2.3$460.18+0.4%$188.64 billion$23.89 billion73.16Increase in Short Interest
Texas Instruments logo
TXN
Texas Instruments
2.3$186.23+0.4%$172.14 billion$14.38 billion35.20Upcoming Earnings
Analyst Report
SAP logo
SAP
SAP
1.4$139.40+0.1%$171.41 billion$30.86 billion30.24Upcoming Earnings
Analyst Report
T-Mobile US logo
TMUS
T-Mobile US
1.6$129.45+2.0%$164.04 billion$45.00 billion42.30Analyst Report
Analyst Revision
QUALCOMM logo
QCOM
QUALCOMM
2.5$134.22+0.8%$153.64 billion$23.53 billion29.63Dividend Increase
Analyst Report
Shopify logo
SHOP
Shopify
1.4$1,149.52+0.3%$140.39 billion$1.58 billion732.18
SONY
Sony Group
0.0$109.53+0.4%$134.19 billionN/A0.00
Applied Materials logo
AMAT
Applied Materials
2.3$130.72+0.1%$120.11 billion$17.20 billion33.35Analyst Report
International Business Machines logo
IBM
International Business Machines
2.4$139.39+4.5%$118.96 billion$77.15 billion15.79Earnings Announcement
Analyst Report
News Coverage
Gap Down
Square logo
SQ
Square
1.3$250.44+2.0%$111.53 billion$4.71 billion397.53Analyst Report
Intuit logo
INTU
Intuit
2.4$402.41+0.0%$110.16 billion$7.68 billion54.01
ServiceNow logo
NOW
ServiceNow
1.9$549.43+0.0%$107.73 billion$3.46 billion155.65Analyst Report
Uber Technologies logo
UBER
Uber Technologies
1.8$57.03+1.4%$107.65 billion$14.15 billion-14.33Analyst Report
Airbnb logo
ABNB
Airbnb
1.1$171.64+1.7%$106.22 billionN/A0.00
Micron Technology logo
MU
Micron Technology
2.2$88.17+0.3%$99.14 billion$21.44 billion33.27
Advanced Micro Devices logo
AMD
Advanced Micro Devices
1.8$80.08+1.3%$98.52 billion$6.73 billion108.22Upcoming Earnings
Insider Selling
Zoom Video Communications logo
ZM
Zoom Video Communications
1.5$324.20+0.0%$95.26 billion$622.66 million415.64Analyst Report
Snap logo
SNAP
Snap
1.5$58.99+2.5%$91.16 billion$1.72 billion-78.65Upcoming Earnings
Analyst Upgrade
Insider Selling
Lam Research logo
LRCX
Lam Research
2.2$620.35+0.2%$88.85 billion$10.04 billion35.19Upcoming Earnings
Analyst Report
Analyst Revision
Dell Technologies logo
DELL
Dell Technologies
1.7$102.19+1.2%$78.88 billion$92.15 billion32.14Analyst Report
Increase in Short Interest
Infosys logo
INFY
Infosys
1.4$17.99+1.5%$77.47 billion$12.78 billion30.49Earnings Announcement
Analyst Report
VMware logo
VMW
VMware
1.1$166.51+2.1%$71.28 billion$10.81 billion44.28Insider Selling
Analyst Revision
Baidu logo
BIDU
Baidu
1.9$208.41+0.7%$70.45 billion$15.43 billion20.97Decrease in Short Interest
NetEase logo
NTES
NetEase
1.8$105.97+0.8%$69.61 billion$8.51 billion34.68
Snowflake logo
SNOW
Snowflake
1.1$226.49+1.1%$66.13 billionN/A0.00
Autodesk logo
ADSK
Autodesk
1.7$288.28+0.7%$63.73 billion$3.27 billion150.15
Twilio logo
TWLO
Twilio
1.6$372.40+1.3%$62.64 billion$1.13 billion-131.13Analyst Report
Insider Selling
Workday logo
WDAY
Workday
1.4$254.63+0.0%$61.85 billion$3.63 billion-136.17Insider Selling
Analog Devices logo
ADI
Analog Devices
2.2$155.74+0.8%$57.88 billion$5.60 billion47.48Unusual Options Activity
Koninklijke Philips logo
PHG
Koninklijke Philips
1.0$59.99+1.1%$54.88 billion$21.82 billion42.55Upcoming Earnings
News Coverage
Twitter logo
TWTR
Twitter
1.3$67.22+1.1%$54.26 billion$3.46 billion-48.71Analyst Report
NXP Semiconductors logo
NXPI
NXP Semiconductors
2.1$195.10+0.2%$53.70 billion$8.88 billion-368.11Upcoming Earnings
Relx logo
RELX
Relx
1.6$26.90+0.1%$52.03 billion$10.05 billion22.61
Vodafone Group logo
VOD
Vodafone Group
1.8$18.62+2.3%$51.10 billion$50.00 billion30.03News Coverage
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.